The effect of non-steroidal anti-inflammatory drugs on bleeding, platelet function and consumption of opiates following cardiac surgery
| ISRCTN | ISRCTN14974395 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14974395 |
| Secondary identifying numbers | 0120-430/2016-2 |
- Submission date
- 07/04/2018
- Registration date
- 25/04/2018
- Last edited
- 30/03/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Surgery
Plain English summary of protocol
Background and study aims
The pain following heart surgery is mostly associated with sternotomy (surgical procedure to divide the sternum), pericardiectomy (removal of the membrane around the heart), chest tube insertion, and the removal of a vein from a patient's leg. Traditionally, intravenous opioids are used for pain management after heart surgery.
However, their use is associated with side effects, such as nausea, vomiting, itching, urinary
retention, intestinal paresis, and respiratory depression. Long-acting opioids administered after surgery postpone the removal of the ventilation tube in the windpipe (extubation) due to increased sedation and respiratory depression (inadequate slow and shallow breathing).
A combination of nonsteroidal anti-inflammatory drugs (NSAID) and opioid analgetics has been recommended for pain relief after major surgeries. The need of opioid analgesics can be reduced by using NSAIDs, thus also reducing the side effects of opioid analgesics, especially nausea and vomiting. The combination of NSAID and opioid analgesics contributes to an earlier extubation and patient mobilisation leading to an early discarge from the ICU.
The aim of the study is to confirm whether NSAID diclofenac decreases the use of opioid analgesics following cardiac surgery during the first 20 hours after surgery.
Who can participate?
Adults aged 20 – 85 years undergoing elective cardiac surgery
What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group receive intravenous Diclofenac after cardiac surgery, whilst those in the control group receive intravenous saline. Participants are followed up for 20 hours after surgery.
What are the possible benefits and risks of participating?
There are no specific benefits or risks for those taking part in the study.
Where is the study run from?
University Medical Centre Maribor (Slovenia)
When is the study starting and how long is it expected to run for?
May 2016 to December 2018
Who is funding the study?
University Medical Centre Maribor (Slovenia)
Who is the main contact?
Mrs Irena Osojnik (Scientific)
irena.ogrizek@guest.arnes.si
Contact information
Scientific
University Medical Centre Maribor
Ljubljanska ulica 5
Maribor
2000
Slovenia
| Phone | + 386 51 243 260 |
|---|---|
| irena.ogrizek@guest.arnes.si |
Study information
| Study design | Single-centre prospective randomised controlled study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | The effect of diclofenac on bleeding, platelet function, and the use of opiates following coronary artery bypass graft |
| Study objectives | The purpose of the study is to establish whether using diclofenac after a coronary artery bypass graft (CABG) with extracorporeal circuit decreases the consumption of opioid analgesics and their side effects. It also aims to establish whether diclofenac disrupts the platelet function and consequently increases bleeding and transfusion of blood and blood products after cardiac surgery. |
| Ethics approval(s) | 1. Commission of the Republic of Slovenia for Medical Ethics (Komisija Republike Slovenije za medicinsko etiko), 22/08/16, ref: 0120-430 2. Republic of Slovenia National Medical Ethics Committee (NMEC) 10/08/2016, ref: 2016-2 |
| Health condition(s) or problem(s) studied | Cardiac surgery |
| Intervention | After cardiac surgery, participants are randomised to one of two treatment groups using coin randomisation. 1. The treatment group receive an intravenous infusion of 75 mg diclofenac (250 ml Neodolpasse) within 90 minutes to three hours after cardiac surgery, and again after 12 hours. 2. The control group receive an infusion of 250 ml of saline (0.9% NaCl) within 90 minutes to three hours after surgery, and again after 12 hours. Both groups are followed up 20 hours after surgery. Both groups receive intravenous bolus piritramid 0.05 mg/kg body weight every six hours for postoperative pain relief. In addition to basal pain relief the patients receive additional piritramid 0.025 mg/kg on request by means of nurse controlled analgesia to achieve adequate analgesia (NRS ≤ 3). |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | |
| Drug / device / biological / vaccine name(s) | Diclofenac |
| Primary outcome measure | 1. Pain is measured using the NRS (numerical rating scale) for pain assessment at 1 hour intervals until 20 hours after surgery 2. The use of piritramide is recorded within the first 20 hours after surgery 3. The use of blood and blood product is recorded within the first 20 hours after surgery |
| Secondary outcome measures | 1. Heamodynamic data (invasive blood pressure and heart rate) is measured using Phillips MX 800 monitor at 1 hour intervals until 20 hours after surgery 2. Sternal drain blood loss is measured using Sternal drainage system Atrium at 1 hour intervals until 20 hours after surgery 3. Time to extubation and time of ICU stay is recorded. 4. Unfavourable side effects are recorded during the ICU stay |
| Overall study start date | 01/05/2016 |
| Completion date | 30/12/2018 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 60 |
| Total final enrolment | 72 |
| Key inclusion criteria | 1. Adult aged 20 - 85 years 2. Operated for elective cardiac surgery using extracorporeal circuit |
| Key exclusion criteria | 1. History of peptic ulcer disease, gastointestinal bleeding 2. Renal and liver insufficiency 3. Allergy for nonsteroidal analgetics 4. Increased bleeding during surgery 5. Increased bleeding after surgery, as defined by the chest tube drainage of more than 300 ml per hour during the first 3 hours after surgery. |
| Date of first enrolment | 30/10/2016 |
| Date of final enrolment | 30/08/2018 |
Locations
Countries of recruitment
- Slovenia
Study participating centre
+386 51 243 260
Slovenia
Sponsor information
Hospital/treatment centre
Medical Research Department
Ljubljanska ulica 5
Maribor
2000
Slovenia
| Phone | +386 321 1000 |
|---|---|
| irena.osojnik@ukc-mb.si | |
"ROR" |
https://ror.org/02rjj7s91 |
Funders
Funder type
Hospital/treatment centre
No information available
Results and Publications
| Intention to publish date | 30/06/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Planned publication of results in Medical Journals. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request. Additional documents are available upon request from the author. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 07/11/2019 | 30/03/2020 | Yes | No |
Editorial Notes
30/03/2020: The following changes have been made:
1. Publication reference added.
2. The total final enrolment number has been added from the reference.
